RCS - Immupharma PLC - ‘Investor Meet Company’ presentation on 20 March

ImmuPharmaAnnouncement

Today 07:00

For best results when printing this announcement, please click on link below:
https://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20260318:nRSR0290Xa&default-theme=true

RNS Number : 0290X  Immupharma PLC  18 March 2026

18 March 2026 | RNS REACH

 

 

 

 

ImmuPharma PLC

("ImmuPharma" or the "Company")

 

ImmuPharma to present live on 'Investor Meet Company' platform

Friday 20 March 2026 @ 12:00 (GMT)

ImmuPharma PLC (LSE AIM:), the specialty biopharmaceutical company that
discovers and develops peptide-based therapeutics is pleased to announce that
ImmuPharma's Tim McCarthy, CEO, Dr Sébastien Goudreau, CSO, and Dr Tim
Franklin, COO, will provide a live presentation relating to the Company's
announcement, released on Tuesday 17 March 2026, titled:

 

P140 Update - remains on track for licensing deal in 2026

Accelerated Development of Kapiglucagon for Type 1 Diabetes

Subscription & WRAP Retail Offer to raise up to £7.5 million

 

https://www.immupharma.co.uk/investors/regulatory-news/
(https://www.immupharma.co.uk/investors/regulatory-news/)

The live presentation, via the 'Investor Meet Company' platform, will be held
on Friday 20 March 2026 @ 12:00 (GMT).

The presentation is open to all existing and potential shareholders. Questions
can be submitted pre-event via your Investor Meet Company dashboard until 19
March 2026, 09:00am (GMT), or at any time during the live meeting. No new
material will be shared at this presentation.

Investors can sign up to Investor Meet Company for free and add to meet
ImmuPharma PLC via:
via: https://www.investormeetcompany.com/immupharma-plc/register
(https://www.investormeetcompany.com/immupharma-plc/register) .

 

Investors who already follow ImmuPharma PLC on the Investor Meet Company
platform, will automatically be invited.

 

The presentation will also be available post the live meeting, on ImmuPharma's
website: https://www.immupharma.co.uk/updates/interviews/
(https://www.immupharma.co.uk/updates/interviews/) .

 

 

Ends

 

 

 

 

 

 For further information please contact:

ImmuPharma PLC (www.immupharma.co.uk (http://www.immupharma.co.uk) )  +44 (0) 207 206 2650

 Tim McCarthy, Chief Executive Officer and Chairman

 Lisa Baderoon, Head of Investor Relations                             + 44 (0) 7721 413496

 SPARK Advisory Partners Limited (NOMAD)                               +44 (0) 203 368 3550

 Neil Baldwin

 Stanford Capital Partners (Joint Broker)                              +44 (0) 203 650 3650/51

 Patrick Claridge, Bob Pountney

 SI Capital (Joint Broker)                                             +44 (0) 1483 413500

 Nick Emerson

Notes to Editors

 

About ImmuPharma PLC

 

ImmuPharma PLC (LSE AIM: IMM) is a specialty biopharmaceutical company that
discovers and develops peptide-based therapeutics. The Company's portfolio
includes novel peptide therapeutics for autoimmune diseases and
anti-infectives.

 

For additional information about ImmuPharma please visit www.immupharma
(https://www.immupharma.co.uk/) .co.uk (https://www.immupharma.co.uk/)

 

ImmuPharma's LEI (Legal Entity Identifier) code : 213800VZKGHXC7VUS895.

 

 

About Investor Meet Company

Investor Meet Company provides a digital platform that enables individual
investors and wealth managers to access live, interactive presentations by
UK-listed companies, regardless of their shareholding, size or location. For
more information go to: https://www.investormeetcompany.com
(https://www.investormeetcompany.com) .

About RNS REACH Announcements

Reach is an investor communication service aimed at assisting listed and
unlisted (including AIM quoted) companies to distribute media only /
non-regulatory news releases such as marketing messages, corporate and product
information into the public domain. An RNS Regulatory announcement is required
to be notified under the AIM Rules for Companies.

 

 

 

 

This information is provided by Reach, the non-regulatory press release distribution service of RNS, part of the London Stock Exchange. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  NRAAKOBDOBKDKND



            Copyright 2019 Regulatory News Service, all rights reserved